Market Size & Forecast

The viral vector and plasmid DNA manufacturing market was valued at US $5.33 billion in 2023 and is projected to reach US $19.50 billion by 2030, exhibiting a robust CAGR of 20.3%.

Another credible estimate places it at US $5.37 billion in 2023, with a forecast of nearly US $34 billion by 2033, translating to a CAGR of 20.25%.

Introduction & Definition

Viral vectors are genetically engineered viruses used to deliver therapeutic genetic material into human cells—forming the backbone of gene therapies, DNA vaccines, and cell & gene products. Plasmid DNA, circular bacterial DNA containing a gene of interest, supports protein expression and serves as a template for viral vector production. Together, they are critical to molecular medicine, offering high transfection efficiency, stable gene expression, and scalable manufacturing for modern therapies.

Segmentation Analysis

• By Product Type:
   Viral vectors—including AAV, lentivirus, adenovirus, retrovirus—dominate revenue (over 20% from AAV segment alone in 2023), while plasmid DNA is essential for upstream production.
  

• By Application:
   Use cases include cancer gene therapy, vaccines, genetic disorders—cancer leads with nearly 38% market share, driven by CAR-T and tumor gene therapies. Rapid vaccine development during COVID-19 highlighted plasmid DNA’s role as transcriptional template.
  

• By End‑User / Workflow:
  Major buyers are biopharma manufacturers, CDMOs, and research institutions. Integrated, single-use bioreactor workflows are promising for scalable production and cost reduction.
  

Geographical Insights

• North America holds about 49% of the global market in 2023, driven by U.S. biotech leadership, CDMO infrastructure, regulatory support, and a dense pipeline of advanced therapies.
  

• Europe captures around 27%, led by Germany, UK, and France, supported by EMA-backed ATMP frameworks.
  

• Asia-Pacific is the fastest-growing region, projected to exceed 17% share by 2023, with China, Japan, South Korea, and India expanding production capabilities and CDMO investments.

  To get a sample report, click on https://www.datamintelligence.com/download-sample/toxoplasmosis-testing-market

Latest News & Industry Trends (US & Japan)

• United States:
  • Investment in automation and digitalization of biomanufacturing, including AI-based process optimization.
   • Notable partnerships aimed at boosting AAV manufacturing capacity, such as Oxford Biomedica’s collaborations.
  

• Japan:
  • Government incentives aimed at building domestic plasmid DNA production and vector CDMO capacity.
  • Innovation in HEK‑Omics is enhancing rAAV production yields and consistency.

Competitive Landscape

Key players in the market include:

• Thermo Fisher Scientific
  

• Merck KGaA
  

• Fujifilm Diosynth Biotechnologies
  

• Cobra Biologics
  

• SIRION Biotech
  

• Lonza
  

• Brammer Bio
  

These firms are expanding capacity through new GMP facilities, acquisitions, and alliances. Fujifilm Diosynth partnered with Chimeron Bio for saRNA vaccines, and Merck established partnerships targeting Asian markets.

Impact Analysis

• Clinical Innovation: Availability of high-quality vectors accelerates the development of CAR-T, gene editing (CRISPR), and rare disease therapies.
  

• Efficiency: Automation and single-use technologies improve reproducibility and lower costs.
  

• Regulatory Support: Frameworks from agencies like the FDA and EMA enable compliant manufacturing for ATMPs.
  

• Global Accessibility: Increased production capacity in Asia helps address supply bottlenecks and market access issues.

Key Developments

• 2022–2023: Emergence of AI-driven biomanufacturing, increasing yields and consistency.
  

• 2019: Thermo Fisher launched a $90 million viral vector CDMO facility in Lexington, MA.
  

• Ongoing: HEK‑Omics–driven optimizations are setting new standards in rAAV vector production efficiency.

About Us

DataM Intelligence is a trusted market research and consulting firm offering deep insights into global biotechnology, life sciences, and healthcare markets. We provide strategic intelligence, forecasts, and trend tracking to empower businesses and policymakers worldwide.

Contact Us

DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877‑441‑4866